-
I dumped it a long time ago winner69. Management didn't seem up to the job. Haven't followed it since
-
some impressive growth here:
Revenue from continuing operations, up 61% to $20.3 million (FY10: $12.6 million);
Earnings Before Interest and Tax (EBIT), up 904% to $3.8 million (FY10: $0.4 million);
Net Profit After Tax (NPAT), up 770% to $2.6 million (FY10: $0.3 million);
Market cap just under $30m, revenues and margins are likely to continue to expand.
Nice exposure to mining (XRF manufactures equipment and chemicals, which are distributed to laboratories in
Australia and overseas and used in the preparation of samples for analysis).
Dividends reinstated as well.
Share prices follow earnings....buy EPS growth!!
-
G'day Steve
Geos love their XRF machines! Sometimes I think they rely on them too much.
Almost as ubiquitous as the rock hammer these days!
-
Could XRF be a T/O target for the likes of CPB. I will have XRF on my to buy list.
They actually have CPB as one of their clients.
-
Agree with that, soulman. I've long seen XRF as a potential target for CPB who have a track record of taking out smaller firms in their wider field of scientific testing and analysis.
I hold quite a few CPB, one of my best ASX performers of recent years. Otherwise, might have already had a nibble at XRF!
-
A decent result. Bought some for their dividends.....
I just like coy with net cash position and pay dividends with the likes of FWD, BSA, XRF, MND, GNG all in buy on weakness watchlist.
-
Originally Posted by steve fleming
some impressive growth here:
Revenue from continuing operations, up 61% to $20.3 million (FY10: $12.6 million);
Earnings Before Interest and Tax (EBIT), up 904% to $3.8 million (FY10: $0.4 million);
Net Profit After Tax (NPAT), up 770% to $2.6 million (FY10: $0.3 million);
Market cap just under $30m, revenues and margins are likely to continue to expand.
Had a look at this because of the announced SCT joint venture for FY2013. Growth in eps terms not as impressive as you think because many new shares were issued in the Sigma Chemicals purchase and FY2010 being the year most affected by the GFC.
I calculate eps/dps figures as follows:
2008: 1.0, 0
2009: 2.1, 0.5
2010: 0.6, 0.75
2011: 2.8, 0
2012: 2.8, 1.0
Nevertheless the margins are decent ( FY2011: 14.2%, FY2012 13.8% ) with ROE quite respectable considering the company has no debt now ( FY2011: 14.8%, FY2012 13.5% ).
At 25.5c XFR is on an historic PE of 9.1. Probably about right considering some customers might be having a tougher year in FY2013.
SNOOPY
Last edited by Snoopy; 10-12-2012 at 03:37 PM.
Watch out for the most persistent and dangerous version of Covid-19: B.S.24/7
-
https://stocknessmonster.com/announc....asx-6A992651/
A great presentation.
Yet another of DMX's portfolio that I followed them into.
www.dmxam.com.au
Last edited by percy; 25-08-2020 at 11:59 AM.
-
https://stocknessmonster.com/announc...asx-6A1002762/
Another positive presentation.
Interesting noting a new machine for a new sector.Look forward to more details.
To save hiccups with their divie, I elected to take DRP.New shares were allocated a few days ago.
Last edited by percy; 23-10-2020 at 12:52 PM.
-
Member
What price did you enter at Percy? This looks like one of those stocks that flies under the radar. Has quietly improved earnings and divs over the past few years. I have a small parcel, considering increasing my stake.
Posting Permissions
- You may not post new threads
- You may not post replies
- You may not post attachments
- You may not edit your posts
-
Forum Rules
|
|
Bookmarks